Immatics (IMTX) Cash from Financing Activities (2019 - 2025)
Immatics recorded quarterly Cash from Financing Activities of $115.9 million in Q4 2025, up 13604.66% quarter-over-quarter from -$858086.4 in Q3 2025, and down 25.91% year-over-year from $156.4 million in Q4 2024.
Immatics' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $115.9 million for Q4 2025.
- In Q4 2025, Cash from Financing Activities fell 25.91% year-over-year to $115.9 million; the TTM figure through Dec 2025 stood at $113.4 million (down 67.09% YoY), while the FY2025 annual figure was $110.0 million, down 67.8% from the prior year.
- Cash from Financing Activities came in at $115.9 million for Q4 2025 at Immatics, up from -$858086.4 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $189.7 million in Q1 2024 to a low of -$1.0 million in Q4 2023.
- A 5-year average of $33.7 million and a median of -$639942.7 in 2021 frame the typical range for Cash from Financing Activities.
- Across the five-year window, Cash from Financing Activities sank 482.48% in 2021 and surged 20511.49% in 2024, its largest moves.
- Immatics' Cash from Financing Activities stood at -$670367.0 in 2021, then soared by 16154.62% to $107.6 million in 2022, then tumbled by 100.97% to -$1.0 million in 2023, then surged by 15054.62% to $156.4 million in 2024, then decreased by 25.91% to $115.9 million in 2025.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $115.9 million, -$858086.4, and -$822934.7 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -802.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Immatics | 1.80 Bn | 1.80 Bn | - | 115.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 115.88 Mn |
| Dec 31, 2025 | 115.88 Mn |
| Sep 30, 2025 | -858,086.44 |
| Sep 30, 2025 | -858,086.44 |
| Jun 30, 2025 | -822,934.69 |
| Jun 30, 2025 | -822,934.69 |
| Mar 31, 2025 | -775,238.83 |
| Mar 31, 2025 | -775,238.83 |
| Dec 31, 2024 | 156.40 Mn |
| Dec 31, 2024 | 156.40 Mn |
| Sep 30, 2024 | -826,959.29 |
| Sep 30, 2024 | -826,959.29 |
| Jun 30, 2024 | -609,518.37 |
| Jun 30, 2024 | -609,518.37 |
| Mar 31, 2024 | 189.73 Mn |
| Mar 31, 2024 | 189.73 Mn |
| Dec 31, 2023 | -1.05 Mn |
| Dec 31, 2023 | -1.05 Mn |
| Sep 30, 2023 | 54.32 Mn |
| Sep 30, 2023 | 54.32 Mn |
| Jun 30, 2023 | 39.69 Mn |
| Jun 30, 2023 | 39.69 Mn |
| Mar 31, 2023 | -929,514.02 |
| Mar 31, 2023 | -929,514.02 |
| Dec 31, 2022 | 107.62 Mn |
| Dec 31, 2022 | 107.62 Mn |
| Sep 30, 2022 | 3.04 Mn |
| Sep 30, 2022 | 3.04 Mn |
| Jun 30, 2022 | 16.96 Mn |
| Jun 30, 2022 | 16.96 Mn |
| Mar 31, 2022 | -773,290.69 |
| Mar 31, 2022 | -773,290.69 |
| Dec 31, 2021 | -670,366.98 |
| Dec 31, 2021 | -670,366.98 |
| Sep 30, 2021 | -800,736.09 |
| Sep 30, 2021 | -800,736.09 |
| Jun 30, 2021 | -1.04 Mn |
| Jun 30, 2021 | -1.04 Mn |
| Mar 31, 2021 | -581,405.81 |
| Mar 31, 2021 | -581,405.81 |
| Dec 31, 2020 | 175,266.61 |
| Dec 31, 2020 | 175,266.61 |
| Sep 30, 2020 | 244.02 Mn |
| Sep 30, 2020 | 244.02 Mn |
| Jun 30, 2020 | -613,513.29 |
| Jun 30, 2020 | -613,513.29 |
| Mar 31, 2020 | -674,506.74 |
| Mar 31, 2020 | -674,506.74 |
| Dec 31, 2019 | -516,916.54 |
| Dec 31, 2019 | -516,916.54 |
| Sep 30, 2019 | -558,590.48 |
| Sep 30, 2019 | -558,590.48 |